CUSIP: 481116101
Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
34,310,812
-
Share change
-
-1,571,097
-
Total reported value
-
$63,468,853
-
Put/Call ratio
-
4.1%
-
Price per share
-
$1.85
-
Number of holders
-
83
-
Value change
-
+$5,857,432
-
Number of buys
-
40
-
Number of sells
-
39
Quarterly Holders Quick Answers
What is CUSIP 481116101?
CUSIP 481116101 identifies JNCE - JOUNCE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2023
-
Previous quarter:
Q4 2022
Recent filing periods for CUSIP 481116101:
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q1 2023
As of 31 Mar 2023,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
83 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
34,310,812 shares.
The largest 10 holders included
TANG CAPITAL MANAGEMENT LLC, Deep Track Capital, LP, Tudor Investment Corp Et Al, Opaleye Management Inc., BlackRock Inc., VANGUARD GROUP INC, Erste Asset Management GmbH, JPMORGAN CHASE & CO, BML Capital Management, LLC, and Ardent Capital Management, Inc..
This page lists
83
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.